A caveolin binding motif in Na/K-ATPase is required for stem cell differentiation and organogenesis in mammals and C. elegans – Science Advances

INTRODUCTION Embryonic development is characterized by the temporal and spatial regulation of cell proliferation, migration, differentiation, and tissue formation. Although these processes are genetically determined, several signaling mechanisms including Wnt have been recognized as essential in regulating cell lineage specification and organogenesis (13). The Na/Kadenosine triphosphatase (ATPase) (NKA), discovered in crab nerve fibers by Skou (4), belongs to the P-type ATPase superfamily

Read more
Human Embryonic Stem Cells (HESC) Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 – News Distinct

The Human Embryonic Stem Cells (HESC) Market is analyzed in depth in the report, with the main aim of providing precise market data and useful recommendations so that players can achieve strong growth in the future. The report is compiled by experienced experts and market analysts, which makes it very authentic and reliable.

Read more
COVID-19: Potential impact on Human Embryonic Stem Cells (HESC) Market: Strategic Analysis to Understand the Competitive Outlook of the Industry, 2026…

In 2029, the Human Embryonic Stem Cells (HESC) market is spectated to surpass ~US$ xx Mn/Bn with a CAGR of xx% over the forecast period. The Human Embryonic Stem Cells (HESC) market clicked a value of ~US$ xx Mn/Bn in 2018. Region is expected to account for a significant market share, where the Human Embryonic Stem Cells (HESC) market size is projected to inflate with a CAGR of xx% during the forecast period.

Read more
Tolero Pharmaceuticals Presents Findings from First Clinical Studies Evaluating Investigational Agents TP-1287 and TP-3654 in Patients with Advanced…

SALT LAKE CITY, Utah, May 29, 2020 /PRNewswire/ --Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented data from the first clinical studies evaluating the oral investigational agents TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, and TP-3654, a PIM kinase inhibitor, in patients with advanced solid tumors. These results were presented in poster presentations at the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting, being held May 29-31, 2020.

Read more